<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03513172</url>
  </required_header>
  <id_info>
    <org_study_id>15-9762-B</org_study_id>
    <nct_id>NCT03513172</nct_id>
  </id_info>
  <brief_title>Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy</brief_title>
  <official_title>Hypotensive Efficacy of Topical Prophylaxis for Intraocular Pressure Spikes Following Intravitreal Injections of Anti-vascular Endothelial Growth Factor Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Efrem Mandelcorn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators will be examining the intraocular pressure lowering effect of
      brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 55 consecutive patients undergoing anti-VEGF intravitreal injections (received ≥1
      treatments) for age-related macular degeneration (AMD), diabetic macular edema (DME) or
      macula edema secondary to branch retinal vein occlusion (BRVO) will be prospectively
      recruited between December 2016 and July 2017. Patients will be randomly assigned based on a
      pre-determined allocation sequence to receive topical brimonidine tartrate 0.15% (Alphagan®
      P; Allergan, Inc) during either the first or second of two consecutive visits. A standard
      protocol for sterile preparation with topical 5% povidone-iodine solution will be followed.
      Pre-injection IOP measurements will be recorded prior to the instillation of dilating agents
      and brimonidine tartrate. A total of three IOP measurements will be taken by certified
      ophthalmic technicians at immediately after the injection (T0), 10 minutes after (T10) and 20
      minutes after (T20) injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Actual">September 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Post-Injection Intraocular Pressure Spike</measure>
    <time_frame>Change from immediately, 10 minutes and 20 minutes after injection</time_frame>
    <description>the intraocular pressure lowering effect of brimonidine 0.15% ophthalmic eye drop when administered 20 minutes prior to intravitreal anti-VEGF injection</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Post-Injection Intraocular Pressure Spikes</condition>
  <arm_group>
    <arm_group_label>Brimonidine Pre-Administration During First Visit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine Pre-Administration During Second Visit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)</intervention_name>
    <description>The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.</description>
    <arm_group_label>Brimonidine Pre-Administration During First Visit</arm_group_label>
    <arm_group_label>Brimonidine Pre-Administration During Second Visit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  received ≥1 treatments for age-related macular degeneration (AMD), diabetic macular
             edema (DME) or macula edema secondary to branch retinal vein occlusion (BRVO)

        Exclusion Criteria:

          -  baseline diagnosis of glaucoma

          -  baseline IOP during last visit of greater than 21 mmHg

          -  ongoing use of topical medications (eg. corticosteroids)

          -  pseudophakic with an anterior chamber intraocular lens

          -  history of ocular conditions that may impact IOP (eg. pseudoexfoliation)

          -  previous in-office (eg. laser peripheral iridotomy) and vitreoretinal surgical
             procedures (eg. pars plana vitrectomy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Efrem Mandelcorn, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <reference>
    <citation>Kampougeris G, Spyropoulos D, Mitropoulou A. Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Possible Mechanisms and Correlations. J Curr Glaucoma Pract. 2013 Jan-Apr;7(1):19-24. doi: 10.5005/jp-journals-10008-1132. Epub 2013 Jan 15. Review.</citation>
    <PMID>26997776</PMID>
  </reference>
  <reference>
    <citation>Kim YJ, Sung KR, Lee KS, Joe SG, Lee JY, Kim JG, Yoon YH. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol. 2014 Jun;157(6):1266-1271.e1. doi: 10.1016/j.ajo.2014.02.035. Epub 2014 Feb 18.</citation>
    <PMID>24561173</PMID>
  </reference>
  <reference>
    <citation>Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012 Feb;119(2):321-6. doi: 10.1016/j.ophtha.2011.08.011. Epub 2011 Nov 4.</citation>
    <PMID>22054994</PMID>
  </reference>
  <reference>
    <citation>Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson JA, Freund KB. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012 Apr-May;21(4):241-7. doi: 10.1097/IJG.0b013e31820d7d19.</citation>
    <PMID>21423038</PMID>
  </reference>
  <reference>
    <citation>Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol. 2012 Mar;23(2):105-10. doi: 10.1097/ICU.0b013e32834ff41d. Review.</citation>
    <PMID>22249237</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Tina Felfeli</investigator_full_name>
    <investigator_title>Medical Student</investigator_title>
  </responsible_party>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Anti-VEGF Agents</keyword>
  <keyword>alpha2-agonists</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

